All canine diagnoses

Your dog was diagnosed with Prostatic Carcinoma. Uncommon but highly aggressive. Occurs in BOTH castrated and intact male dogs (unlike benign prostatic hyperplasia which is only intact). Some evidence that neutered dogs may be at equal or higher risk. Typically presents with dysuria, haematuria, or hindlimb stiffness from sublumbar LN or skeletal metastasis. Compare 3 treatment options for dogs including Piroxicam (NSAID) Monotherapy, Radiation Therapy (IMRT/Palliative), Palliation (Stenting + Pain Management) — with survival times, costs, and what to expect during treatment.

🐕

Prostatic Carcinoma

BreedsBouvier des FlandresDoberman PinscherShetland SheepdogScottish TerrierBeagleGerman Shorthaired Pointer
canine

Epithelial

About This Cancer

Prostatic carcinoma is an aggressive cancer arising from the glandular or transitional cells of the prostate gland. An important distinction from benign prostatic enlargement (which affects only intact male dogs) is that prostatic cancer occurs in both castrated and intact dogs — in fact, some evidence suggests neutered dogs may be at equal or even higher risk, though this relationship is still being studied. The tumour is locally invasive, often extending into the urethra and trigone of the bladder, and has a high rate of spread to the sublumbar lymph nodes and to bone — particularly the lumbar spine and pelvis, which can cause hind-limb stiffness or pain. It typically presents with difficulty urinating, bloody urine, or straining to defecate. The prognosis is generally poor, as the cancer is usually advanced at diagnosis and complete surgical removal is rarely feasible. Treatment focuses on pain management, maintaining urinary function, and slowing progression.

No universally adopted staging system

Staged by local extent, lymph node, skeletal, and distant metastasis

Stage LocalTumour confined to prostate
Stage RegionalSublumbar lymph node involvement and/or urethral extension
Stage DistantSkeletal metastasis (axial skeleton, pelvis) or pulmonary metastasis
Prognostic Factors(2)
Skeletal metastasis at diagnosisCommon (42% at diagnosis in some series). Significantly shortens survival and indicates systemic disease.
Urethral/trigone involvementLimits surgical options. Causes dysuria requiring palliation.
Minimum Workup(7 steps)
1Rectal palpation (prostatomegaly, asymmetry, pain)
2Abdominal ultrasound (prostatic architecture, sublumbar LN)
3CT/MRI for extent of disease (urethral involvement, skeletal mets)
4Thoracic radiographs and lumbar spine radiographs (bone mets common)
5Urinalysis and culture (UTI common concurrent finding)
6BRAF mutation test (urine-based — TCC component common in prostatic tumours)
7Prostatic FNA or biopsy (catheter biopsy technique available)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Piroxicam (NSAID) Monotherapy
~3 mo (2–6)
Radiation Therapy (IMRT/Palliative)
~22 mo (12–36)
Palliation (Stenting + Pain Management)
~2 mo (1–4)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.